Pharmacology for Nurses · Lower Respiratory Disorder Drugs
Adrenergics and Anticholinergics
On this page 9 sections
In 30 seconds
Adrenergics and anticholinergics are the two classic Bronchodilator A drug that widens the airways Full entry → families — the drugs that open narrowed airways in asthma and chronic obstructive pulmonary disease (COPD). They achieve the same clinical result (wider airways, easier breathing) by pushing on opposite sides of the autonomic nervous system, which is the key insight that ties the whole topic together:
- Adrenergics mimic the sympathetic ("fight-or-flight") branch. They stimulate beta-2 adrenergic receptors on airway smooth muscle, which relaxes that muscle directly — the airways dilate.
- Anticholinergics block the parasympathetic ("rest-and-digest") branch. They antagonize muscarinic receptors (especially M3) on airway smooth muscle, removing the vagus nerve's constant constricting signal — the airways dilate.
Normal airway caliber is a tug-of-war between sympathetic relaxation and parasympathetic constriction. Bronchodilators work by strengthening one side of the tug-of-war or untying the other. Within the adrenergic class, the duration of action matters enormously: short-acting beta-2 agonists (SABAs) are the rescue drugs for sudden symptoms, while long-acting beta-2 agonists (LABAs) are maintenance therapy — and for asthma, LABAs are never used alone. Anticholinergics such as ipratropium (short-acting) and tiotropium (long-acting) are central to COPD management and have a supporting role in asthma exacerbations. Because these drugs are inhaled, correct Inhaler technique The correct steps for delivering inhaled medication to the lungs Full entry → is as much a nursing responsibility as knowing the pharmacology.
Why this matters
Asthma and COPD together affect hundreds of millions of people worldwide, and bronchodilators are the backbone of symptom management in both. This topic matters to nurses because:
- Rescue vs. maintenance Acute-relief drug vs. daily controller drug Full entry → is a safety distinction. A person who needs their rescue inhaler constantly is poorly controlled — recognizing that pattern and escalating it to the prescriber is a core nursing responsibility. Conversely, LABA Long-acting beta-2 agonist (e.g., salmeterol, formoterol) — 12+ hour maintenance Full entry → monotherapy in asthma is unsafe (associated with increased risk of severe asthma events), so nurses verify that a LABA is always paired with an inhaled corticosteroid.
- Mechanism explains assessment. Knowing that beta-2 stimulation affects more than the lungs — heart rate, tremor, potassium — tells the nurse what to look for after a treatment.
- Inhaler technique determines effectiveness. A large fraction of people use inhalers incorrectly; nurses teach, observe, and correct technique, which is often more impactful than the drug choice.
- COPD care is multi-drug. Anticholinergics, LABAs, and inhaled corticosteroids are combined in endless permutations; nurses must understand the classes to teach what each inhaler is for.
The college version
Core Concepts
The autonomic tug-of-war on airway caliber
Airway smooth muscle wraps the bronchi like a spiral of rubber bands. Two branches of the autonomic nervous system control how tight those bands are:
- Sympathetic activation (via circulating epinephrine and beta-2 receptors on the muscle) relaxes the bands — bronchodilation.
- Parasympathetic (vagal) tone (via acetylcholine acting on M3 muscarinic receptors) tightens the bands — bronchoconstriction. This vagal tone is continuous, which is why blocking it has a measurable effect even at rest.
In asthma and COPD, inflammation, triggers, and disease-related changes shift the balance toward constriction. Bronchodilators correct the balance pharmacologically: adrenergics add relaxation signal; anticholinergics remove constriction signal.
Adrenergic bronchodilators: beta-2 agonists
Beta-2 agonists activate beta-2 adrenergic receptors on airway smooth muscle, raising intracellular cyclic AMP (cAMP), which leads to muscle relaxation. They are the most effective acute bronchodilators and come in two clinically vital flavors:
- Short-acting beta-2 agonists (SABAs) — e.g., albuterol (salbutamol). Onset within minutes; effect lasts a few hours. These are the rescue drugs for acute bronchospasm, exercise-induced bronchospasm, and exacerbations. "Reliever" is their job description.
- Long-acting beta-2 agonists (LABAs) — e.g., salmeterol, formoterol. Onset is slower and the effect lasts 12 hours or more. They are maintenance/controller drugs. In asthma, LABAs are used only in combination with an inhaled corticosteroid — LABA monotherapy carries an increased risk of severe asthma-related events and must never be the sole asthma therapy. In COPD, LABA-inhaled-corticosteroid combinations are also common, and treatment decisions follow current guidelines and prescriber orders.
Expected adverse effects follow directly from beta-2 receptor biology: the receptors also live in the heart and skeletal muscle. Tachycardia, palpitations, tremor, and nervousness are common; hypokalemia can occur with high doses. These effects are generally dose-related and more prominent with systemic (oral/injected) use than inhaled use.
Anticholinergic bronchodilators: muscarinic antagonists
Anticholinergics block muscarinic receptors (M3) on airway smooth muscle, preventing acetylcholine from signaling constriction. Because they remove cholinergic (vagal) tone, they are particularly effective in COPD — where vagal tone contributes substantially to airway narrowing — and they do not cause the tremor or tachycardia of beta-2 agonists. Two duration flavors again:
- Short-acting (SAMA) — e.g., ipratropium. Used for acute relief; in asthma it plays a supporting role in exacerbations alongside a SABA Short-acting beta-2 agonist (e.g., albuterol) — fast rescue relief Full entry →.
- Long-acting (LAMA) — e.g., tiotropium. A cornerstone of COPD maintenance therapy, often combined with a LABA.
Adverse effects are anticholinergic and mostly local: dry mouth, bitter taste, and occasionally urinary retention or worsening of narrow-angle glaucoma (especially if the drug reaches the eye). Inhaled anticholinergics are poorly absorbed, so systemic effects are limited but not zero — individual risk varies and should be verified against references and the person's history.
Choosing and combining: asthma vs. COPD
A simplified map (guidelines and prescriber orders always govern actual treatment):
- Asthma — inhaled corticosteroids are the foundation of controller therapy; SABAs are the rescue therapy; LABAs only in combination with inhaled corticosteroids; anticholinergics mainly in exacerbations.
- COPD — bronchodilation is the foundation: SABAs/SAMAs and LABAs/LAMAs, often combined, with inhaled corticosteroids added for specific indications (e.g., frequent exacerbations).
- In both, the nurse's job is to know which inhaler is which, confirm the person can use each correctly, and recognize when symptoms outpace the plan.
Nursing considerations
- Assessment: before a bronchodilator treatment, assess breath sounds, respiratory rate/effort, oxygen saturation, and heart rate; after treatment, reassess to document response.
- Technique: teach and return-demonstrate inhaler technique — spacer use, breath-hold, and (for dry-powder inhalers) the specific priming steps; verify against the product's instructions for use.
- Sequence when multiple inhalers are ordered: if a bronchodilator and a corticosteroid inhaler are both ordered, the bronchodilator is generally taken first to open the airways so the steroid reaches deeper — but always follow the prescriber's explicit instructions and the institution's protocol.
- Monitoring: watch for tachycardia, tremor, worsening symptoms, or no response to rescue therapy — the latter is a red flag requiring immediate reevaluation.
- Education: teach the difference between rescue and maintenance inhalers, when to seek help, and how to track symptoms; emphasize that a LABA is never the only asthma medication.
- Scope: verification of orders, formulary products, and local policy governs everything a nurse administers or recommends.
Common Confusions
| Do Not Confuse | With | Difference |
|---|---|---|
| Adrenergic (adds relaxation signal) | Anticholinergic (removes constriction signal) | Same goal, opposite sides of the autonomic nervous system |
| SABA | LABA | SABA = fast, short rescue; LABA = slow-onset, long maintenance — and LABA is never asthma monotherapy |
| Beta-2 selectivity | "No heart effects" | Beta-2 agonists still cause tachycardia/tremor via dose-related effects and receptor overlap |
| Anticholinergic bronchodilator | Antihistamine | Anticholinergics block muscarinic receptors in airways; antihistamines block H1 receptors in allergy |
| "Reliever" inhaler | "Controller" inhaler | Reliever = as-needed rescue; controller = scheduled maintenance; using one as the other is unsafe |
| COPD treatment plan | Asthma treatment plan | Bronchodilation is foundational in COPD; inhaled corticosteroids are foundational in asthma — LABA alone is contraindicated in asthma |
Eli explains
The same idea, in plain words
Explain it like I’m 10
Your breathing tubes are like rubber hoses with two strings pulling on them: one string (the "go" system) pulls them open, and the other string (the "rest" system) pulls them closed. When they get squeezed too tight, you can't breathe well. Adrenergic drugs grab the "open" string and pull harder — the hose opens up. Anticholinergic drugs untie the "closed" string so it stops pulling — the hose opens up too. Two different strings, same result: a wider tube and easier breathing.
Worked example
Amara, 34, is admitted with an asthma exacerbation after several days of worsening symptoms. Her chart shows she was prescribed a SABA inhaler for rescue and a combination inhaler containing a LABA plus an inhaled corticosteroid for daily use — a plan consistent with current asthma guidance, since the LABA is never used alone. The nurse assesses her: audible wheezing, increased respiratory rate, oxygen saturation at the low end of the target range. After confirming the orders, the nurse gives the prescribed SABA treatment, then reassesses — breath sounds, effort, saturation, and heart rate — documenting improvement.
Before discharge, the nurse watches Amara use each inhaler. She presses the rescue inhaler without a spacer and exhales into the mouthpiece — a common error that wastes most of the dose. The nurse demonstrates, has Amara return-demonstrate until the technique is smooth, and reviews the plan: rescue inhaler for sudden symptoms, controller inhaler daily as ordered, and the warning signs (no relief from rescue therapy, night waking, rapid worsening) that mean she needs evaluation immediately rather than "riding it out." Amara also learns that her controller inhaler contains the LABA and corticosteroid together — and that the LABA-containing product must never be her only asthma medicine. Every product, dose, and teaching point is verified against the discharge orders and the current formulary before the nurse documents and hands off.
Key takeaways
- Adrenergics = beta-2 agonists — add sympathetic relaxation signal; anticholinergics = muscarinic (M3) antagonists — remove parasympathetic constriction signal.
- SABA (e.g., albuterol) = fast-onset rescue; LABA (e.g., salmeterol, formoterol) = long-acting maintenance.
- LABA monotherapy in asthma is unsafe — LABAs must be paired with an inhaled corticosteroid; this is a critical safety point.
- Beta-2 adverse effects: tachycardia, tremor, nervousness, possible hypokalemia with high doses.
- Anticholinergic adverse effects: dry mouth, bitter taste; caution regarding urinary retention and glaucoma — verify individual risk.
- Anticholinergics are central to COPD maintenance (LAMA); in asthma they are mainly adjuncts during exacerbations.
- Nursing: assess before/after treatment, teach and return-demonstrate inhaler technique, and escalate when rescue therapy is not working.
- All therapy follows current guidelines, the formulary, and prescriber orders — never memorized recipes.
Check yourself
6 review questions from the chapter. Try each one, then open the answer.
Through which receptor and mechanism does an adrenergic bronchodilator open the airways?
Show answer
Beta-2 adrenergic receptors on airway smooth muscle; activation raises cAMP and relaxes the muscle (sympathetic-mimicking bronchodilation).
Through which receptor does an anticholinergic bronchodilator open the airways?
Show answer
Muscarinic (M3) receptors; blocking them prevents acetylcholine from signaling constriction, removing parasympathetic tone.
Why is LABA monotherapy unsafe in asthma, and what must accompany a LABA?
Show answer
LABA monotherapy is associated with an increased risk of severe asthma-related events; it must always be paired with an inhaled corticosteroid in asthma.
A person reports hand tremor and a racing heart after using their inhaler. Which class of drug explains this, and why?
Show answer
Beta-2 agonists (adrenergics). Beta-2 receptors outside the lung — including heart and skeletal muscle — cause dose-related tachycardia, tremor, and nervousness.
What is the difference between a SABA and a LAMA in terms of onset, duration, and typical role?
Show answer
A SABA (e.g., albuterol) is fast-onset, short-duration rescue therapy; a LAMA (e.g., tiotropium) is slower-onset, long-duration maintenance therapy, central to COPD.
What are two nursing actions that improve how well inhaled bronchodilators actually work?
Show answer
Teach and verify correct inhaler technique (including spacers), and assess breath sounds and response before and after treatment. (Also: ensure the right inhaler is used for the right purpose — rescue vs. maintenance.)
Study tools & related lessonsKey vocabulary · Related
Key vocabulary
- Bronchodilator
- A drug that widens the airways
- Beta-2 adrenergic receptor
- The sympathetic receptor on airway smooth muscle that causes relaxation when activated
- Muscarinic (M3) receptor
- The parasympathetic receptor that causes airway constriction when activated
- SABA
- Short-acting beta-2 agonist (e.g., albuterol) — fast rescue relief
- LABA
- Long-acting beta-2 agonist (e.g., salmeterol, formoterol) — 12+ hour maintenance
- SAMA / LAMA
- Short-/long-acting muscarinic antagonists (e.g., ipratropium / tiotropium)
- Rescue vs. maintenance
- Acute-relief drug vs. daily controller drug
- Inhaler technique
- The correct steps for delivering inhaled medication to the lungs
Sources & references
This lesson was adapted from the open educational references above; their licenses and attributions are preserved. See Copyright & Licensing.
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.